Risperidone-ISM® effectiveness and tolerability in acute schizophrenia patients hospitalised due to a relapse: results from an international, prospective, non-interventional evaluation (RESHAPE study)
6 hours ago
- #long-acting injectable
- #Risperidone-ISM
- #schizophrenia
- Risperidone-ISM® was evaluated for effectiveness and tolerability in hospitalized schizophrenia patients experiencing relapse.
- Significant improvements in CGI-S and PANSS-6 scores were observed as early as day 8, continuing through day 56.
- Median discharge time was 8 days after the first Risperidone-ISM® injection.
- Functional improvement was noted with a 17.6-point increase in PSP scores by day 28.
- 78% of patients reported satisfaction with treatment, and therapeutic alliance improved in 89.4% of participants.
- No new safety concerns were reported, with only 4% discontinuing due to adverse events.
- Adding another antipsychotic did not provide additional benefits.
- Results support Risperidone-ISM® for acute schizophrenia relapse treatment in real-world settings.